检索结果-南通市图书馆

Rare esophageal carcinoma-primary adenoid cystic carcinoma of the esophagus: A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第3期12卷 630-636页

作者： Li-Dan Geng Jie Li Li Yuan Xiao-Bo Du department of oncology Mianyang Central HospitalMianyang 621000Sichuan ProvinceChina

BACKGROUND Esophageal adenoid cystic carcinoma(EACC)is an exceedingly rare malignant tumor of the esophagus,posing significant challenges in the *** SUMMARY This report detailed the case of a 72-year-old male whose diagnosis of EACC was confirmed through postoperative histopathological *** patient underwent thoracoscopy-assisted radical resection of the esophageal tumor,coupled with lymph node *** findings revealed an adenoid cystic carcinoma infiltrating the entire layer of the muscularis propria,locally extending into the outer membrane of the esophageal fiber,involving the cardia and exhibiting no lymph node *** patient’s condition was classified as primary EACC,T3N0M0,per the American Joint Committee on Cancer(2017;8th edition).One month after surgery,the patient received postoperative adjuvant radiation *** In addressing the rarity and high potential for biopsy misdiagnosis of EACC,this study delved into its diagnostic methods and treatment.

关键词： Esophageal adenoid cystic carcinoma Malignant tumor Lymph node dissection Adjuvant radiation therapy Misdiagnosis Case report

The real-world study of the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Pancreatology 2024年第1期7卷 1-9页

作者： Jiujie Cui Qihan Fu Xiaobing Chen Yanling Wang Qi Li Feng Wang Zhihua Li Guanghai Dai Yusheng Wang Hongmei Zhang Houjie Liang Jun Zhou Liu Yang Fenghua Wang Leizhen Zheng Xiaofeng Chen Ping Gong Jiang Liu Ying Yuan Lin Wang Yuejuan Cheng Jun Zhang Yuhong Zhou Weijian Guo Xianbao Zhan Zhengyun Zou Da Li Shan Zeng Enxiao Li Zhiwei Li Zan Teng Dan Cao Jie Kan Jianping Xiong Ming Quan Jiayu Yao Haiyan Yang Liwei Wang department of Medical oncology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghaiChina department of Medical oncology The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouChina department of Medical oncology Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouChina department of Medical oncology Shanghai General HospitalShanghai Jiao Tong UniversityShanghaiChina department of Medical oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina department of Medical oncology Sun Yat-sen Medical Hospital Sun Yat-sen UniversityGuangzhouChina Medical oncology Chinese PLA General HospitalBeijingChina department of Gastrointestinal oncology Shanxi Provincial Cancer HospitalAffiliated to Shanxi Medical UniversityTaiyuanChina department of Clinical oncology Xijing HospitalAir Force Medical UniversityXi’anChina department of oncology and Southwest Cancer Center Southwest HospitalThird Military Medical University(Army Military Medical University)ChongqingChina department of Gastrointestinal oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital&InstituteBeijingChina Cancer Center Department of Medical OncologyZhejiang Provincial People’s HospitalPeople’s Hospital of Hangzhou Medical CollegeHangzhouChina department of Medical oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongChina oncology department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of MedicineShanghaiChina department of oncology the First Affiliated Hospital with Nanjing Medical UniversityNanjingChina department of oncology The First Affiliated HospitalSchool of MedicineShihezi UniversityShiheziChina department of oncology People’s Hospital of Xinjiang Uygur Autonomous RegionXinjiangChina department of Medical oncology t

Objective:Real-world diagnostic and treatment data for pancreatic cancer in China are *** such,the present study investigated the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer(including locally advanced and metastatic disease)in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center ***:A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a *** entire course of real-world pancreatic cancer management was ***:The proportion of patients with advanced pancreatic cancer was higher among males than females(62.4%vs 37.6%,respectively).Patients typically had a history of hypertension(30.8%),diabetes(21.6%),and cholangitis(20.2%).Abdominal pain(51.6%),abdominal distension(27.1%),jaundice(20.1%),and weight loss(16.3%)were the main symptoms observed in patients with advanced pancreatic cancer in this *** carbohydrate antigen(CA)19-9 is one of the most common tumor *** the present study,2562 patients underwent first-line *** median progression-free survival(PFS)for patients undergoing first-line therapy was 4.1 *** major options for first-line therapy included gemcitabine(GEM)plus S-1(GS/X)(23.4%),nab-paclitaxel plus GEM(AG)(18.1%),oxaliplatin,irinotecan,and leucovorin-modulated fluorouracil(FOLFIRINOX;11.9%),nab-paclitaxel plus S-1(AS)(8.9%),and GEM combined with oxaliplatin/cisplatin(GEMOX/GP)(7.6%).The AS and GS/X regimens were associated with the highest PFS ***:This is the first study to report multicenter,real-world data regarding advanced pancreatic cancer in *** revealed that real-world treatment options differed from guideline recommendations,and PFS was shorter than that in previously reported *** intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

关键词： Advanced pancreatic cancer China Pancreas Data Center Chinese First-line regimens Real-world study

Stereotactic body radiotherapy in pancreatic adenocarcinoma

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2024年第1期23卷 14-19页

作者： Carolina de la Pinta Radiation oncology department Ramón y Cajal University HospitalIRYCISAlcaláUniversity28034 MadridSpain

Background:Stereotactic body radiotherapy(SBRT)in pancreatic cancer allows high delivery of radiation doses on tumors without affecting surrounding *** review aimed at the SBRT application in the treatment of pancreatic *** sources:We retrieved articles published in MEDLINE/PubMed from January 2017 to December *** used in the search included:“pancreatic adenocarcinoma”OR“pancreatic cancer”AND“stereotactic ablative radiotherapy(SABR)”OR“stereotactic body radiotherapy(SBRT)”OR“chemoradiotherapy(CRT)”.English language articles with information on technical characteristics,doses and fractionation,indications,recurrence patterns,local control and toxicities of SBRT in pancreatic tumors were *** articles were assessed for validity and relevant ***:Optimal doses and fractionation have not yet been ***,SBRT could be the standard treatment in patients with pancreatic adenocarcinoma in addition to ***,the combination of SBRT with chemotherapy may have additive or synergic effect on pancreatic ***:SBRT is an effective modality for patients with pancreatic cancer,supported by clinical practice guidelines as it has demonstrated good tolerance and good disease *** opens a possibility of improving outcomes for these patients,both in neoadjuvant treatment and with radical intent.

关键词： Chemoradiotherapy Pancreatic adenocarcinoma Radiotherapy Stereotactic body radiotherapy Stereotactic ablative radiotherapy

Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology

在线全文

学校读者我要写书评

暂无评论

Genes & Diseases 2024年第2期11卷 807-818页

作者： Yingying He Hui Yu Shuang Dai Miao He Ling Ma Zihan Xu Feng Luo Li Wang oncology department Deyang People's HospitalDeyangSichuan 618000China department of Medical oncology Lung Cancer CenterWest China HospitalSichuan UniversityChengduSichuan 610000China Cardiovascular department Mianyang Central HospitalMianyangSichuan 621000China department of Rheumatology and Immunology Deyang People's HospitalDeyangSichuan 618000China

Immune checkpoint inhibitors (ICIs) are monoclonal antibody antagonists,which can block cytotoxic T lymphocyte antigen-4 (CTLA-4),programmed death-1/ligand-1 (PD-1/PD-L1) pathways,and other molecules exploited by tumor cells to evade T cell-mediated immune *** have transformed the treatment landscape for various cancers due to their amazing *** anti-tumor therapies,including targeted therapy,radiotherapy,and chemotherapy,combine ICIs to make the treatment more ***,the off-target immune activation caused by ICIs may lead to a broad spectrum of immune-related adverse events (irAEs) affecting multiple organ *** irAEs,cardiotoxicity induced by ICIs,uncommon but fatal,has greatly offset survival benefits from ICIs,which is heartbreaking for both patients and ***,such cardiotoxicity requires special vigilance,and it has become a common challenge both for patients and *** article reviewed the clinical manifestations and influence of cardiotoxicity from the view of patients and clinicians,elaborated on the underlying mechanisms in conjunction with animal studies,and then attempted to propose management strategies from a cardio-immuno-oncology multidisciplinary perspective.

关键词： Cancer management Cardio-immuno-oncology multidisciplinary Cardiotoxicity Immune checkpoint inhibitors Immune tolerance

Neiguan(PC6) acupoint stimulation for preventing chemotherapy-induced nausea and vomiting: a cost-effective supplement in guideline-inconsistent chemotherapy-induced nausea and vomiting prophylaxis subgroup

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Traditional Chinese Medicine 2024年第3期44卷 581-585页

作者： YU Wenxi TANG Lina LI Hongtao WANG Yonggang SHEN Zan department of oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

OBJECTIVE: To assess the efficacy and safety of Neiguan(PC6) acupoint acustimulation in preventing chemotherapy-induced nausea and vomiting(CINV),especially for patients with guideline-inconsistent CINV prophylaxis(GICP) due to personal reasons METHODS: From January 2021 to December 2021, 373 patients suffered from solid malignancy were recruited according to the inclusion criteria. Complete response(no emesis and no rescue medication use) rate during the overall phase(0-120 h of each chemo-cycle) was the primary assessment of CINV control. The Functional Living Index-Emesis(FLIE) questionnaire was investigated among these patients as a secondary 'quality of life' objective to assess the impact of CINV on patients' daily life by recording score of nausea and vomiting. RESULTS: With acustimulation of Neiguan(PC6) acupuncture point through a portable, noninvasive and user-friendly device, in terms of complete response rate and scores in nausea/vomiting by FLIE questionnaire, patients achieve a better outcome in highly emetogenic chemotherapy(HEC) induced CINV, especially GICP subgroup. Meanwhile, analysis also demonstrated this tendency existed in other patients with HEC/GCCP(guideline consistent CINV prophylaxis) and moderate emetogenic chemotherapy, although the difference was not significant. CONCLUSION: Considering advantages of Neiguan(PC6) acustimulation such as noninvasive, covered by medical insurance and few side effects, we believe it would be an ideal auxiliary tool in CINV control, especially in patients who receive highly emetogenic chemoprotocol and are reluctant to GCCP for economic reasons.

关键词： acupuncture acustimulation chemotherapy-induced nausea and vomiting tumor

Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase Ⅱ trial

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2024年第5期21卷 433-444页

作者： Shuzhen Lai Peijing Li Xiaohui Liu Guihong Liu Tieming Xie Xing Zhang Xiaoxuan Wang Jing Huang Yiqiang Tang Zhigang Liu Guoping Shen Chaoming Li Fangxiao Lu Lei Wang Fagui Jiang Caixing Sun Yuanyuan Chen Ming Chen department of Radiation oncology The Second Affiliated Hospital of Soochow UniversitySuzhou 215000China department of Radiation oncology Yuebei People’s Hospital Affiliated to the Medical College of Shantou UniversityShaoguan 512026China Chinese Academy of SciencesHangzhou 310022China department of Radiation oncology The Second Clinical Medical College of Zhejiang Chinese Medical UniversityHangzhou 311403China department of Radiation oncology The Affiliated Hospital of Xuzhou Medical UniversityXuzhou 221004China Chinese Academy of SciencesHangzhou 310022China State Key Laboratory of Translational Medicine and Innovative Drug Development Jiangsu Simcere Diagnostics Co.LtdNanjing 210000China department of Radiation oncology The Affiliated Huai’an First People’s Hospital of Nanjing Medical UniversityHuai’an 223399China department of Radiation oncology Jiangxi Cancer Hospital of Nanchang UniversityNanchang 330029China department of Radiotherapy Dongguan Institute of Clinical Cancer ResearchDongguan Key Laboratory of Precision Diagnosis and Treatment for TumorsAffiliated Dongguan HospitalSouthern Medical UniversityDongguan 523059China The Cancer Center The Fifth Affiliated Hospital of Sun Yat-Sen UniversityZhuhai 519000China department of Radiation oncology The First Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou 510080China department of oncology Maoming People’s HospitalMaoming 525000China department of Radiation oncology Kecheng District People’s HospitalQuzhou 324003China Chinese Academy of SciencesHangzhou 310022China department of Radiation oncology State Key Laboratory of Oncology in South ChinaSun Yat-sen University Cancer CenterGuangzhou 510060China United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University&Chinese Academy of Sciences Ion Medical Technology Co. LtdGuangzhou 510060China

Objective:Glioblastomas are highly vascularized malignant *** determined the efficacy and safety of the anti-angiogenic multi-kinase inhibitor,anlotinib,for a newly diagnosed ***:This multicenter,single-arm trial(NCT04119674)enrolled 33 treatment-naïve patients with histologically proven glioblastomas between March 2019 and November *** underwent treatment with the standard STUPP regimen[fractionated focal irradiation in daily fractions of 1.8-2 Gy given 5 d/w×6 w(total=54-60 Gy)]or radiotherapy plus continuous daily temozolomide(TMZ)(75 mg/m^(2)of body surface area/d,7 d/w from the first to the last day of radiotherapy),followed by 6 cycles of adjuvant TMZ(150-200 mg/m^(2)×5 d during each 28-d cycle)plus anlotinib(8 mg/d on d 1-14 of each 3-w cycle for 2 cycles during concomitant chemoradiotherapy,8 maximal cycles as adjuvant therapy,followed by maintenance at 8 mg/*** primary endpoint was progression-free survival(PFS).Secondary endpoints included overall survival(OS)and adverse events(AEs).Results:Thirty-three patients received the planned *** median PFS was 10.9 months(95%CI,9.9-18.7 months)and the 12-month PFS rate was 48.5%.The median OS was 17.4 months(95%CI,14.5-21.1 months)and the 12-month OS rate was 81.8%.The most common AEs included hypertriglyceridemia[58%(n=19)],hypoalbuminemia[46%(n=15)],and hypercholesterolemia[46%(n=15)]during concurrent chemoradiotherapy and leukopenia[73%(n=24)],hypertriglyceridemia[67%(n=22)],and neutropenia[52%(n=17)]during adjuvant *** patients discontinued treatment due to ***1(HR,5.6;95%CI,1.3-23.7;P=0.021)and RP1L1 alterations(HR,11.1;95%CI,2.2-57.2;P=0.004)were associated with a significantly shorter ***:Anlotinib plus the STUPP regimen has promising anti-tumor activity against glioblastoma and manageable ***1 and RP1L1 alterations might be novel predictive biomarkers of the response to anlotinib.

关键词： Glioblastoma anti-angiogenesis multi-kinase inhibitor anlotinib temozolomide progression-free survival

Genomic medicine and cancer clinical trial in Thailand

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2024年第1期21卷 10-15页

作者： Lucksamon Thamlikitkul Napa Parinyanitikul Virote Sriuranpong Division of Medical oncology Department of MedicineFaculty of Medicine Siriraj HospitalMahidol UniversityBangkok 10700Thailand Division of Medical oncology Department of MedicineFaculty of MedicineChulalongkorn University&The King Chulalongkorn Memorial HospitalBangkok 10330Thailand

Introduction Cancer treatment has been revolutionized with the advent of targeted therapy and *** the past,when cancer treatment modalities were restricted,conventional chemotherapy was the only option for systemic *** chemotherapy empirically affects all dividing cells,the targets are virtually *** this regard,toxic effects on normal tissue are essentially inevitable.

关键词： chemotherapy cancer Cancer

Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy:Two case reports

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第7期12卷 1296-1304页

作者： Dan Wu Qiong Wang Shuai Yan Xia Sun Ya Qin Ming Yuan Nan-Yao Wang Xian-Ting Huang department of oncology Jiangyin People's HospitalWuxi 214400Jiangsu ProvinceChina

BACKGROUND Pancreatic cancer is a highly malignant *** decades of treatment progress,the current five-year survival rate for patients is still less than 10%.For later-line treatment,the treatment options are even more ***-angiogenic drugs can improve progression-free survival in patients with advanced pancreatic *** data show that fruquintinib might improve the prognosis of advanced pancreatic cancer by targeting angiogenesis and lymphopoiesis,improving the abnormal vascular structure,and modulating the tumour immune *** SUMMARY We present two cases of third-line fruquintinib monotherapy that brought an extraprolonged progress-free survival(PFS)of 10 *** 1 took adjuvant gemcitabine-based and first-line nab-paclitaxel-based chemotherapy and then used local radiotherapy combined with programmed cell death 1 receptor(PD-1).Each line lasted approximately 7 ***,the patient took third-line fruquintinib,which was followed by stable disease for 10 months,during which no additional adverse effect was *** patient later refused to take fruquintinib due to difficulty urinating and lower abdominal pain after the coronavirus disease 2019(COVID-19)*** patient died in February *** 2 also took two prior lines of chemotherapy and then local radiotherapy combined with *** confirmed disease progression,the patient experienced a continuous partial response after using fruquintinib monotherapy in the third *** the patient had COVID-19 in December 2022,fruquintinib was *** patient died in January 2023 due to disease *** Both cases achieved a PFS benefit from later-line single-agent fruquintinib *** its better safety profile,fruquintinib may be worth exploring and studying in more depth as a later-line treatment for pancreatic cancer patients.

关键词： Pancreatic cancer Anti-vascular endothelial growth factor receptor Fruquintinib Case report

Immunotherapy in gastric cancer with liver metastasis:Challenges and opportunities

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Surgery 2024年第6期16卷 1513-1516页

作者： Murat Bardakçi Yakup Ergun department of Medical oncology Diyarbakır Gazi Yasargil Training and Research HospitalDiyarbakir 021000KayapinarTürkiye department of Medical oncology Antalya City HospitalAntalya 07080Türkiye

In this editorial,we review the article by Liu et al published in the World Journal of Gastrointestinal Surgery investigating the efficacy and safety of immunotherapy in patients with gastric cancer(GC)and liver ***,the fifth most com-monly diagnosed malignancy worldwide,presents a significant challenge due to its multifactorial etiology and a grim prognosis for unresectable or recurrent *** advent of immune checkpoint inhibitors(ICIs)has revolutionized oncology;yet liver metastasis has been associated with reduced response rates,progression-free survival,and overall survival in various *** Che-ckMate-649 and KEYNOTE-859 trials demonstrated promising results with ICIs in advanced GC,particularly in patients with liver ***,a meta-analysis of liver metastatic solid tumors revealed worse outcomes with ICIs,high-lighting the need for further *** combined therapies,including ICIs with local treatments,show promise in improving outcomes,the nuanced landscape of ICIs in liver metastatic GC necessitates continued research for robust *** current contradictions in the literature underscore the impor-tance of cautious interpretation and the exploration of tailored approaches to enhance clinical efficacy in this challenging patient population.

关键词： Gastric cancer Liver metastasis Immunotherapy Immune checkpoint in-hibitors Transarterial chemoembolization Tumor microenvironment